Combination therapy with interferon-alpba-2b and hydroxyurea in patients with chronic myelogenous leukemia

European Journal of Internal Medicine

Volumn 10, Issue 1, 1999, Pages 27-31

  Hatzimichael, Eleftheria Chr ^a   Bourantas, Konstantinos L ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Chronic myelogenous leukemia; Hydroxyurea; Interferon alpha 2b

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; HYDROXYUREA;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLYSIS; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFLUENZA; LEUKOCYTE COUNT; MALE; PHILADELPHIA 1 CHROMOSOME; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL;

EID: 0032940527     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(99)00008-4     Document Type: Article

References (32)

1. Silver R.T., Gale R.P. Chronic myeloid leukemia. Am. J. Med. 80:1986;11376-11470.
2. Kantarjian H.M., O'Brien S., Anderlini P., Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 87:1996;3069-3081.
3. Lee S.J., Kuntz K.M., Horowitz M.H.et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann. Intern. Med. 127:1997;1080-1088.
4. Griesshammer M., Arnold R., Bangerter M., Hafner M., Heinze B., Hertenstein B., Heimpel H., Bunjes D. Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur. J. Haematol. 61:1998;7-13.
5. Varbo J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 19:1992;1-10. Suppl 9.
6. Hehlman R., Heimpel H., HasforD J.et al. Randomized comparison of interferon - a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 84:1994;4064-4077.
7. Spiers A.S.D., Lorch C.A., Harisson B.A. Chronic granulocytic leukemia (CGL) in chronic phase with two Ph+ cell lines and suppression of one line by hydroxyurea. Blood. 68(Suppl 1):1986;233a. (abstract 811).
8. Kolitz J.E., Kempin S.L., Schluger A.et al. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin. Oncol. 19:1992;27-35. Suppl 9.
9. Borden E.C., Full L.A. Interferons: biochemical, cell growth, inhibitory and immunological effects. Prog. Hematol. 350:1981.
10. Talpaz M., Kantarjian H.M., McCredie K.B.et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 314:1986;1065.
11. Mahon F.X., Faberes C., Montastruc M., Si-Mour S.et al. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplant. 17:1996;S33-S37. Suppl 3.
12. Niederle N., Kloke O., Osieka R., Wandl U., Opalka B., Schmidt C.G. Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin. Oncol. 14:1987;29-35. Suppl 2.
13. Alimera G., Morra E., Lazzarino M.et al. Interferon-alpha-2b as therapy for patients with Ph-positive chronic myelogenous leukemia. Eur. J. Haematol. 45:1990;25-28. Suppl 52.
14. Bourantas K.L., Syrou M., Tsiara S.T., Danella M., Konstantinides P. Combination therapy with interferon-a-2b and hydroxyurea in accelerated phase of chronic myelogenous leukemia. Acta Hematol. 95:1996;117-121.
15. Kantarjian H.M., Smith T.L., O' Brien S.et al. Prolonged survival following achievement of cytogenetic response with alpha interferon therapy in chronic myelogenous leukemia. Ann. Intern. Med. 122:1995;254-261.
16. The Italian Cooperative Study Group on Chronic Myeloid Leukemia Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330:1994;820-825.
17. The Benelux CML Study Group Randomized study on hydroxyurea alone versus hydro-xyurea combined with low-dose interferon-a2b for chronic myeloid leukemia. Blood. 91:1998;2713-2721.
18. Hehlmann R., Heimpel H., Hossfeld D.K.et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant. 17:1996;521-524. Suppl 3.
19. Anger B., Porzsolt F., Leichtle R., Heinze B., Bartram C., Heimpel H. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut. 58:1989;275-278.
20. Kantarjian H.M., Keating M.J., Smith T.L., Talpaz M., McCredie K.B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med. 88:1990;1-8.
21. Kennedy B.J. The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin. Oncol. 19:1992;21-26.
22. Hehlmann R., Heimpel H. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Leuk. Lymphoma. 22:1996;161-167. Suppl 1.
23. Talpaz M., Kantarjian H., Kuzrock R., Trujillo J., Guttermann J. Interferon alpha produces sustained cytogenetic responses in Philadelphia positive chronic myelogenous leukemia. Ann. Intern. Med. 114:1991;532.
24. Kantarjian H.M., O'Brien S., Anderlini P., Talpaz M. Current status and investigational options. Blood. 87:1996;3069-3081.
25. Kantarjian H.M., Smith T.L., O'Brien S.et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon - a therapy. Intern. Med. 122:1995;254-261.
26. Sacchi S., Kantarjian H.M., O'Brien S.et al. Long term follow up of alpha-interferon-based regimens in patients with late chronic phase myelogenous leukemia. Leukemia. 11:1997;1610-1616.
27. Guilhot F., Dreyfus B., Desmarest M.C.et al. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia. Nouv. Rev. Fr. Hematol. 31:1989;171-173.
28. Hehlmann K., Heimpel H., Hossfeld D.K.et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone marrow Transplant. 17:1996;521-524. Suppl 3.
29. L. Meillon, P. Oropeza, R. Arana et al., Treatment of chronic myelogenous leukemia with alpha-Interferon and Hydroxyurea. La revista de investigacion clinica, 25th Congress, International Society of Hematology (ISH), Cancun, Mexico. Suppl. 285, 1994 Apr. 17-21.
30. H. Kantarjian, M. Talpaz, Results of alpha interferon (IFN) therapy alone and in combination regimens in chronic myelogenous leukemia (CML). J. Interferon. Res., 11 Suppl 1: 127 (Ann, MTG, ISIR, Nice, France, Nov., 3-8, 1991).
31. Shofield J.R., Robinson W.A., Murphy J.R., Rovira D.K. Low doses of Interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann. Intern. Med. 121:1994;736-744.
32. Guillot F., Chastang C., Michallet M.et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med. 337:1997;223-229.